The Academy of Managed Care Pharmacy’s Annual Meeting is a meeting of the pharmacists, payers, providers, and biopharma leaders shaping the future of managed care pharmacy. This year, we’re sharing the conference headlines from AMCP Daily Dose, the official daily news briefing for AMCP members that we produce in partnership with AMCP, to bring our readers up to speed on AMCP 2026.
This year’s meeting highlighted the growing tension between rapid therapeutic innovation and the healthcare system’s ability to deliver it effectively, with discussions spanning the evolving drug pricing landscape, persistent access and adherence challenges for high-impact therapies like semaglutide, and gaps in implementing advances such as CAR T-cell therapy and precision oncology. Speakers also emphasized the need to rethink care delivery at a systems level, particularly as interconnected conditions like obesity, diabetes, and cardiovascular disease continue to reshape population health and long-term cost dynamics.
Read on for the top highlights covered in AMCP Daily Dose!
Meeting Overview
AMCP CEO Discusses What AMCP 2026 Meeting Attendees Can Expect
April 13, 2026
Ahead of the AMCP 2026 meeting in Nashville, Susan Cantrell outlined what attendees can expect, emphasizing a strong focus on the evolving drug pricing policy landscape and health equity. She noted that these themes will shape key discussions as managed care professionals gather to address pressing challenges across the healthcare system.
Access, Coverage, and Cost Dynamics
Studies Suggest Improving GLP-1 Persistence, Coverage May Enhance Outcomes And Reduce Obesity-Related Costs
April 15, 2026
Research presented at the meeting found that gaps in persistence and coverage continue to limit the real-world impact of GLP-1 therapies, with adherence declining significantly over time, particularly among patients facing higher out-of-pocket costs. A separate analysis showed that expanding coverage for treatments like semaglutide may deliver a positive return on investment across stakeholders, including employers and PBMs, despite higher upfront costs.
Clinical Innovation and Therapeutic Advances
AMCP 2026 Presenters Discuss How Rapid Advances In Precision Oncology Are Exposing Testing, Treatment Access, Care Delivery Gaps
April 16, 2026
Presenters at the meeting noted that rapid advances in precision oncology are outpacing managed care’s ability to implement them, with persistent gaps in biomarker testing, treatment access, and care coordination limiting uptake. They also highlighted evolving use of CAR T-cell therapy, including earlier-line treatment and expanded outpatient delivery following recent regulatory changes.
Population Health Trends and Insights
Experts Call For Integrated Approach To Rising Metabolic Disease Burden
April 17, 2026
Experts at the meeting emphasized that metabolic conditions are increasingly interconnected and require a shift from treating individual diseases to a more integrated, system-wide approach. They highlighted obesity as a central driver of related conditions and called for strategies focused on prevention, coordinated care, and long-term economic impact.
For more industry insights like this, follow us on LinkedIn and Instagram!
